Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Exhaled breath condensate (EBC) has emerged as a novel noninvasive technique for assessment of airway inflammation, and it provides information on airway lining fluid composition. Traditionally, such assessment relies on invasive diagnostic tools such as bronchial biopsy and bronchoalveolar lavage (BAL) to obtain specimens from the airway but it is very uncomfortable procedure especially for young patients. The aim of this study is to evaluate the effect of allergic disease, disease monitoring and exposure to tobacco smoke on airway inflammation measured by markers in exhaled breath condensate (EBC) in children with asthma allergic to house dust mite. Also, we aim to assess correlations between cytokine concentrations in EBC and clinical characteristic of the patients with exercise-induced bronchoconstriction as another phenotype of asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Lodz; Medical Universtity of Lodz
• Treatments: Formoterol Fumarate; Montelukast

Criteria

Inclusion Criteria:

• children with mild to moderate asthma allergic to house dust mite exposed/nonexposed to tobacco smoke

• healthy children

Exclusion Criteria:

• sensitization to allergens other than house dust mites

• other chronic diseases

• asthma exacerbation

• pregnancy

• oral corticosteroids for 4 weeks before the study

• montelukast sodium for 2 weeks before the study